eligibility_summary
Adults (≥18) with untreated classical HL stage III/IV, measurable disease, ECOG ≤2, adequate labs (ANC ≥1k, platelets ≥75k, bili <1.5×ULN, AST/ALT <3×ULN, Cr <2 mg/dL or CrCl >30, Hgb ≥8), contraception and consent required. Exclude: pregnancy/lactation, CNS HL, neuro disease/peripheral neuropathy, active infection, recent chemo/radiation/immunotherapy, prior brentuximab, AVD contraindication/allergy, HIV, HBsAg+, active HCV, other recent malignancy, major cardiac disease (LVEF<50%, MI<2y, NYHA III/IV).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 4, single-arm study in India testing brentuximab vedotin plus AVD (doxorubicin, vinblastine, dacarbazine) in untreated stage III/IV classical Hodgkin lymphoma. Drugs and mechanisms: 1) Brentuximab vedotin (ADC): anti‑CD30 monoclonal antibody linked to MMAE, binds CD30 on Hodgkin Reed–Sternberg cells, internalizes, releases microtubule poison → G2/M arrest and apoptosis. 2) Doxorubicin (anthracycline chemo): DNA intercalation, topoisomerase II inhibition, free‑radical DNA damage. 3) Vinblastine (vinca alkaloid): binds tubulin, blocks microtubule polymerization. 4) Dacarbazine (alkylating/methylating prodrug): converts to MTIC, methylates DNA, causing cytotoxic damage. Targets: CD30+ Reed–Sternberg cells, microtubules (MMAE, vinblastine), DNA replication/repair and topoisomerase II (doxorubicin), DNA alkylation/methylation (dacarbazine).